US Bancorp’s Estrella Immunopharma ESLA Stock Holding History

US Bancorp’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-20,000	Closed	-$20.8K	–	4283
2026 Q2	$20.8K	Buy	20,000 +3,096	+18%	+$4.05K	﹤0.01%	3187
2026 Q1	$17.9K	Buy	+16,904	New	+$19.4K	﹤0.01%	3162

Other funds holding ESLA

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

US Bancorp's ESLA Position: Q3 2026 in Review

US Bancorp sold out of Estrella Immunopharma (ESLA) in Q3 2026, closing a stake of 20,000 shares — an estimated $20.8K sold.

US Bancorp first reported a position in ESLA in Q1 2026 and held it in 2 quarters. The position peaked at $20.8K in Q2 2026. 11 funds tracked by Wall St. Rank hold ESLA as of Q3 2026.

US Bancorp reported no remaining Estrella Immunopharma position as of Q3 2026 after selling out during the quarter.
US Bancorp sold 20,000 Estrella Immunopharma shares in Q3 2026, an estimated $20.8K.
US Bancorp first reported a position in Estrella Immunopharma in Q1 2026 and held it in 2 quarters.
US Bancorp's Estrella Immunopharma position peaked at $20.8K in Q2 2026.
11 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.